NA Antimicrobial Susceptibility Testing Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET APPLICATION COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
5 MARKET OVERVIEW 65
5.1 DRIVERS 67
5.1.1 RISE IN EPIDEMIC AND PANDEMIC OUTBREAK 67
5.1.2 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 67
5.1.3 AVAILABILITY OF ADVANCED ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS 68
5.1.4 HIGH PREVALENCE OF INFECTIOUS DISEASES 68
5.1.5 DEVELOPMENT OF NEW GENOMIC IDENTIFICATION METHODS 69
5.2 RESTRAINTS 69
5.2.1 STRINGENT GOVERNMENT REGULATIONS 69
5.2.2 HIGH COSTS OF AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS 69
5.2.3 SHORTAGE OF SKILLED PERSONNEL 70

5.3 OPPORTUNITIES 70
5.3.1 INCREASING PRODUCT LAUNCHES 70
5.3.2 INCREASE IN FUNDING 71
5.3.3 STRATEGIC DECISIONS TAKEN BY KEY MARKET PLAYERS 71
5.4 CHALLENGES 72
5.4.1 EMERGENCE OF LOCAL PLAYERS 72
5.4.2 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 72
5.4.3 LACK OF CLINICAL DATA FROM FDA 73
6 IMPACT OF COVID-19 ON NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 74
6.1 IMPACT ON PRICE 74
6.2 IMPACT ON DEMAND 74
6.3 IMPACT ON SUPPLY 74
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 75
6.5 CONCLUSION: 75
7 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 76
7.1 OVERVIEW 77
7.2 INSTRUMENTS 80
7.2.1 MANUAL 81
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 81
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 81
7.2.1.2.1 DODECA DISCS 82
7.2.1.2.1.1 GENERAL PURPOSE 82
7.2.1.2.1.2 GRAM NEGATIVE ORGANISM 82
7.2.1.2.1.3 GRAM POSITIVE ORGANISM 83
7.2.1.2.1.4 PSEUDOMONAS 83
7.2.1.2.1.5 UTI ORGANISMS 83
7.2.1.2.2 HEXA DISCS 83
7.2.1.2.2.1 GRAM NEGATIVE ORGANISMS 84
7.2.1.2.2.2 GRAM POSITIVE ORGANISMS 84
7.2.1.2.2.3 GENERAL PURPOSE 84
7.2.1.2.2.4 ANAEROBIC BACTERIA 84
7.2.1.2.2.5 ANTIFUNGAL 84
7.2.1.2.2.6 OTHERS 84
7.2.1.2.3 ICOSA DISCS 84
7.2.1.2.3.1 GENERAL PURPOSE 85
7.2.1.2.3.2 PSEUDOMONAS 85
7.2.1.2.3.3 UTI ORGANISMS 85
7.2.1.2.4 OCTO DISCS 85
7.2.1.2.4.1 GRAM NEGATIVE ORGANISMS 86
7.2.1.2.4.2 GRAM POSITIVE ORGANISMS 86
7.2.1.2.4.3 UTI ORGANISMS 86
7.2.1.2.4.4 PSEUDOMONAS 86
7.2.1.2.4.5 GENERAL PURPOSE 86
7.2.1.2.4.6 OTHERS 87
7.2.1.2.5 MIC STRIPS 87
7.2.1.2.5.1 COMBINATION ANTIBACTERIAL 87
7.2.1.2.5.2 DUAL ANTIBACTERIAL 87
7.2.1.2.5.3 MULTIPLE ANTIBACTERIAL 87
7.2.1.2.5.4 SINGLE ANTIBACTERIAL 88
7.2.1.2.5.5 ANTIFUNGAL 88
7.2.1.2.5.6 OTHERS 88
7.3 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 88
7.4 CONSUMABLES & ACCESSORIES 88
7.4.1 REAGENTS & BROTHS 89
7.4.2 MEDIA 89
7.4.3 SUSCEPTIBILITY PANELS 89
7.4.4 OTHERS 90
7.5 SERVICES & SOFTWARE 90
8 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHODS 91
8.1 OVERVIEW 92
8.2 DISK DIFFUSION 95
8.3 DILUTION 95
8.4 MASS SPECTROMETRY METHOD 96
8.5 E-TEST 97
8.6 GENEOTYPIC METHODS 97
8.7 RAPID-AST 98
9 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 99
9.1 OVERVIEW 100
9.2 ANTI BACTERIAL TESTING 103
9.3 ANTI FUNGAL TESTING 103
9.4 OTHERS 104

10 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 105
10.1 OVERVIEW 106
10.2 CLINICAL DIAGNOSTICS 109
10.3 DRUG DISCOVERY AND DEVELOPMENT 109
10.4 EPIDEMIOLOGY 110
10.5 OTHERS 111
11 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 112
11.1 OVERVIEW 113
11.2 HOSPITALS 116
11.3 DIAGNOSTIC LABORATORIES 116
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
11.5 CONTRACT RESEARCH ORGANIZATIONS 118
11.6 RESEARCH CENTRES AND ACADEMIC INSTITUTES 118
11.7 OTHERS 119
12 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 120
12.1 OVERVIEW 121
12.2 DIRECT SALES 124
12.3 RETAIL SALES 124
12.4 THIRD PARTY DISTRIBUTOR 125
13 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 126
13.1 NORTH AMERICA 127
13.1.1 U.S. 137
13.1.2 CANADA 142
13.1.3 MEXICO 147
14 NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 152
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 152
15 SWOT ANALYSIS 153

16 COMPANY PROFILE 154
16.1 THERMO FISHER SCIENTIFIC INC. 154
16.1.1 COMPANY SNAPSHOT 154
16.1.2 REVENUE ANALYSIS 154
16.1.3 COMPANY SHARE ANALYSIS 155
16.1.4 PRODUCT PORTFOLIO 156
16.1.5 RECENT DEVELOPMENTS 157
16.2 BIOMRIEUX SA 158
16.2.1 COMPANY SNAPSHOT 158
16.2.2 REVENUE ANALYSIS 158
16.2.3 COMPANY SHARE ANALYSIS 159
16.2.4 PRODUCT PORTFOLIO 159
16.2.5 RECENT DEVELOPMENTS 160
16.3 MERCK KGAA 161
16.3.1 COMPANY SNAPSHOT 161
16.3.2 REVENUE ANALYSIS 161
16.3.3 COMPANY SHARE ANALYSIS 162
16.3.4 PRODUCT PORTFOLIO 162
16.3.5 RECENT DEVELOPMENTS 163
16.4 DANAHER 164
16.4.1 COMPANY SNAPSHOT 164
16.4.2 REVENUE ANALYSIS 164
16.4.3 COMPANY SHARE ANALYSIS 165
16.4.4 PRODUCT PORTFOLIO 166
16.4.5 RECENT DEVELOPMENTS 167
16.5 ACCELERATE DIAGNOSTICS, INC. 168
16.5.1 COMPANY SNAPSHOT 168
16.5.2 REVENUE ANALYSIS 168
16.5.3 PRODUCT PORTFOLIO 169
16.5.4 RECENT DEVELOPMENTS 169
16.6 ALIFAX S.R.L. 170
16.6.1 COMPANY SNAPSHOT 170
16.6.2 PRODUCT PORTFOLIO 170
16.6.3 RECENT DEVELOPMENTS 171
16.7 BACTERIOSCAN, INC. 172
16.7.1 COMPANY SNAPSHOT 172
16.7.2 PRODUCT PORTFOLIO 172
16.7.3 RECENT DEVELOPMENTS 173

16.8 BD 174
16.8.1 COMPANY SNAPSHOT 174
16.8.2 REVENUE ANALYSIS 174
16.8.3 PRODUCT PORTFOLIO 175
16.8.4 RECENT DEVELOPMENTS 175
16.9 BIO-RAD LABORATORIES, INC. 176
16.9.1 COMPANY SNAPSHOT 176
16.9.2 REVENUE ANALYSIS 176
16.9.3 COMPANY SHARE ANALYSIS 177
16.9.4 PRODUCT PORTFOLIO 177
16.9.5 RECENT DEVELOPMENTS 178
16.10 CREATIVE DIAGNOSTICS 179
16.10.1 COMPANY SNAPSHOT 179
16.10.2 PRODUCT PORTFOLIO 179
16.10.3 RECENT DEVELOPMENTS 180
16.11 ERBA GROUP 181
16.11.1 COMPANY SNAPSHOT 181
16.11.2 PRODUCT PORTFOLIO 181
16.11.3 RECENT DEVELOPMENTS 182
16.12 GENEFLUIDICS, INC. 183
16.12.1 COMPANY SNAPSHOT 183
16.12.2 PRODUCT PORTFOLIO 183
16.12.3 RECENT DEVELOPMENTS 184
16.13 HIMEDIA LABORATORIES 185
16.13.1 COMPANY SNAPSHOT 185
16.13.2 PRODUCT PORTFOLIO 185
16.13.3 RECENT DEVELOPMENTS 186
16.14 LIOFILCHEM S.R.L. 187
16.14.1 COMPANY SNAPSHOT 187
16.14.2 PRODUCT PORTFOLIO 187
16.14.3 RECENT DEVELOPMENTS 188
16.15 MAST GROUP LTD. 189
16.15.1 COMPANY SNAPSHOT 189
16.15.2 PRODUCT PORTFOLIO 189
16.15.3 RECENT DEVELOPMENTS 190
16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 191
16.16.1 COMPANY SNAPSHOT 191
16.16.2 PRODUCT PORTFOLIO 191
16.16.3 RECENT DEVELOPMENTS 192

16.17 NUMEDII, INC. 193
16.17.1 COMPANY SNAPSHOT 193
16.17.2 TECHNOLOGY PORTFOLIO 193
16.17.3 RECENT DEVELOPMENTS 194
16.18 ROSCO DIAGNOSTICA A/S 195
16.18.1 COMPANY SNAPSHOT 195
16.18.2 PRODUCT PORTFOLIO 195
16.18.3 RECENT DEVELOPMENT 195
16.19 SYNBIOSIS 196
16.19.1 COMPANY SNAPSHOT 196
16.19.2 PRODUCT PORTFOLIO 196
16.19.3 RECENT DEVELOPMENTS 197
16.20 ZHUHAI DL BIOTECH CO., LTD 198
16.20.1 COMPANY SNAPSHOT 198
16.20.2 PRODUCT PORTFOLIO 198
16.20.3 RECENT DEVELOPMENT 198
17 QUESTIONNAIRE 199
18 RELATED REPORTS 203